VItiligo RegisTry adUlts And chiLdren-France
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07927699
- Record updated
- 10 November 2026
- Original description
Vitiligo is a chronic skin disorder for which new therapeutic options, including topical and oral Janus kinase (JAK) inhibitors, are emerging. In this evolving therapeutic context, long-term follow-up of patients and documentation of their treatment history are important to better understand treatment outcomes and safety in routine clinical practice.Read full original descriptionShow less
Vitiligo is a chronic skin disorder for which new therapeutic options, including topical and oral Janus kinase (JAK) inhibitors, are emerging. In this evolving therapeutic context, long-term follow-up of patients and documentation of their treatment history are important to better understand treatment outcomes and safety in routine clinical practice.
This study is a French multicenter pilot cohort conducted as a preliminary step toward the development of a national vitiligo registry. It aims to document the clinical course of patients with vitiligo, their treatments and treatment outcomes, and adverse events occurring during treatment. The study will also collect clinical, quality-of-life and patient-reported outcome data and explore potential factors associated with treatment failure or the occurrence of adverse events.
Inclusion: Patient with a diagnosis of vitiligo, with no age restriction; For adult participants: the patient has provided non-opposition to participation in the study; For participants under 18 years of age: the holders of parental authority have provided non-opposition to the child's participation in the study; Patient followed in the dermatology department of a participating center.
Exclusion: Cognitive, mental, or psychiatric disorder that, in the investigator's opinion, prevents completion of the study protocol; Patient under legal protection (guardianship or curatorship); Any difficulty in understanding or reading French that, in the investigator's opinion, could affect the validity of questionnaire completion.